Praeventix Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $4.32M

  • Investors
  • 1

Praeventix General Information

Description

Developer of novel therapeutics intended for serotonergic-driven disorders. The company focuses on discovering, developing, and marketing novel signal transduction-modulating agents for treating inflammatory bowel disease disorders in unmet clinical indications, enabling physicians to provide potential treatment for chronic pruritus.

Contact Information

Website
www.praeventix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 665 Stockton Drive
  • Suite 200H
  • Exton, PA 19341
  • United States
+1 (610)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 665 Stockton Drive
  • Suite 200H
  • Exton, PA 19341
  • United States
+1 (610)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Praeventix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 19-Apr-2023 $4.32M Completed Pre-Clinical Trials
To view Praeventix’s complete valuation and funding history, request access »

Praeventix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed
To view Praeventix’s complete cap table history, request access »

Praeventix Patents

  • 30

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 18

    Pending

  • Expiring in next 12 mo

Praeventix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020381460-A1 Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use Pending 13-Nov-2019
AU-2020383505-A1 Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use Pending 13-Nov-2019
US-20230002383-A1 Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use Pending 13-Nov-2019
EP-4058458-A2 Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use Pending 13-Nov-2019
CA-3161590-A1 Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use Pending 13-Nov-2019 C07D491/107
To view Praeventix’s complete patent history, request access »

Praeventix Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tellus BioVentures Venture Capital Minority
To view Praeventix’s complete investors history, request access »

Ready to get started?

Request a free trial

Praeventix FAQs

  • When was Praeventix founded?

    Praeventix was founded in 2015.

  • Where is Praeventix headquartered?

    Praeventix is headquartered in Exton, PA.

  • What industry is Praeventix in?

    Praeventix’s primary industry is Biotechnology.

  • Is Praeventix a private or public company?

    Praeventix is a Private company.

  • What is the current valuation of Praeventix?

    The current valuation of Praeventix is .

  • What is Praeventix’s current revenue?

    The current revenue for Praeventix is .

  • How much funding has Praeventix raised over time?

    Praeventix has raised $4.32M.

  • Who are Praeventix’s investors?

    Tellus BioVentures has invested in Praeventix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »